OneBAT12/01/2023 - 11/30/2026 (Subcontract PI)
Istituto Zooprofilattico Sperimentale delle Venezie European Commission
National Emerging Infectious Diseases Laboratories Operations07/08/2021 - 06/30/2026 (Key Person)
PI:
Nancy J. Sullivan, ScDNIH/National Institute of Allergy & Infectious Diseases5UC7AI095321-10
Reverse genetic tools and novel models of henipavirus infection10/28/2022 - 09/30/2025 (PI)
Bill and Melinda Gates Foundation
Uncovering the RNA regulatory Mechanisms driving pathogenicity at mass-caualty viruses: Merging the technologies of RNA biology and enhanced biosafety to create the next generation of broad spectrum,10/01/2022 - 09/30/2025 (Multi-PI)
PI:
Elke Muhlberger, PhDHoward Hughes Medical Institute
Uncovering the RNA regulatory mechanisms driving pathogenicity of mass-casualty viruses: Merging the technologies of RNA biology and enhanced biosafety to create the next generation of broad spectrum10/01/2022 - 09/30/2025 (Multi-PI)
PI:
Elke Muhlberger, PhDHoward Hughes Medical Institute
Uncovering the RNA regulatory mechanisms driving pathogenicity of mass-casualty viruses: Merging the technologies of RNA biology and enhanced biosafety to create the next generation of broad spectrum,10/01/2022 - 09/30/2025 (PI)
Howard Hughes Medical Institute
COVID-19 imprints airway basal cells to impair epithelium regeneration08/25/2023 - 07/31/2025 (Subcontract PI)
Massachusetts General Hospital NIH NIAIDR21AI173494-01A1
Mechanisms of Marburg virus gene expression05/08/2018 - 04/30/2025 (Multi-PI)
PI:
Elke Muhlberger, PhDNIH/National Institute of Allergy & Infectious Diseases5R01AI133486-05
Point-of-Care Nanotechnology Diagnostic for Differential Fever Diagnosis10/01/2015 - 10/31/2024 (Co-Investigator of Sub-Project / SP)
Becton, Dickinson and Company Paul G. Allen Fdn
Validating inactivation procedures for biosafety level 4 (BSL-4) viruses for research purposes06/01/2023 - 08/30/2024 (PI)
Georgetown University
Showing 10 of 30 results.
Show All Results
Dissecting the mechanisms of intestinal epithelial injury by Ebola Virus using iPSC-derived intestinal organoids07/05/2022 - 06/30/2024 (Multi-PI)
PI:
Elke Muhlberger, PhDBoston Medical Center Corporation NIH NIAID5R21AI167369-02
Elucidating the immune response of Schreiber's bats to Lloviu virus infection in vitro and in vivo02/24/2022 - 01/31/2024 (PI)
NIH/National Institute of Allergy & Infectious Diseases5R21AI169646-02
Thwarting Influenza with RNA-powered Modulators (ThIRM)03/01/2022 - 03/01/2023 (Subcontract PI)
Georgia Institute of Technology DOD DARPA
COVID Fast Grants05/01/2020 - 02/28/2023 (PI)
Emergent Ventures at the Mercatus Center, George Mason University
Analysis of antibody-dependent enhanced infection by SARSCoV-207/01/2021 - 07/01/2022 (Subcontract PI)
Regeneron Pharmaceuticals, Inc. HHS ASPR BARDA
Deep characterization of the biogenesis and function of Ebola virus microRNAs07/01/2019 - 06/30/2022 (Multi-PI)
PI:
Elke Muhlberger, PhDNIH/National Institute of Allergy & Infectious Diseases5R21AI147285-02
The role of TLR4 signaling in the pathogenesis of filovirus infection05/10/2018 - 04/30/2022 (PI)
NIH/National Institute of Allergy & Infectious Diseases5R21AI135912-02
Deciphering the pathogenic potential of Lloviu virus, a novel filovirus02/13/2018 - 01/31/2022 (PI)
NIH/National Institute of Allergy & Infectious Diseases5R21AI137793-02
Applied Research on Disinfection of Surfaces and Hands to Prevent Novel Coronavirus Transmission07/01/2020 - 12/31/2021 (Subcontract PI)
Trustees of Tufts College, Inc USAID720FDA20GR00137
SARS-CoV-2 infection platforms and development of virological tools to combat the COVID-19 pandemic05/01/2020 - 10/31/2021 (Subcontract PI)
President & Fellows of Harvard College on behalf of Harvard Medical School China Evergrande Gr
National Emerging Infectious Diseases Laboratories Operations06/01/2016 - 07/07/2021 (PI of Sub-Project / SP)
PI:
Ronald B. Corley, PhDNIH/National Institute of Allergy & Infectious Diseases5UC7AI095321-07
Analysis of antibody-dependent enhanced infection by SARS-CoV-210/22/2020 - 06/30/2021 (Subcontract PI)
Regeneron Pharmaceuticals, Inc. HHS ASPR BARDA
Antiviral responses in iPSC-derived human primary cells to Ebola virus infection06/30/2016 - 05/31/2019 (Multi-PI)
PI:
Elke Muhlberger, PhDNIH/National Institute of Allergy & Infectious Diseases5R21AI126457-02
Deep Characterization of Rousettus Aegyptiacus Immune System: Use of bats/nonhuman primates to compare immune responses during asymtomatic/symptomatic filovirus infections01/15/2014 - 06/13/2018 (Subcontract PI)
The Geneva Foundation DOD DTRA
SPR: Novel SPR Barrier Technology (the "USAID Agreement")11/01/2015 - 10/31/2016 (Subcontract PI)
SPR Advanced Technologies Inc. USAID
Filovirus replication: initiation mechanism and role of RNA secondary structures08/05/2014 - 07/31/2016 (PI)
NIH/National Institute of Allergy & Infectious Diseases5R03AI114293-02
Early Host Immune Response in Protection Against Filovirus Infection06/15/2009 - 05/31/2015 (PI)
NIH/National Institute of Allergy & Infectious Diseases5U01AI082954-05
IMVC Pilot Project: Mechanisms of Ebola Virus-induced Vascular Dysfunction05/01/2013 - 04/30/2015 (Subcontract PI)
Augusta University NIH NIAID5U01AI083005-05
National Emerging Infectious Diseases Laboratories Operations06/20/2012 - 07/31/2014 (Sub-Project Level Key Person)
PI:
John R. Murphy, PhDNIH/National Institute of Allergy & Infectious Diseases3UC7AI070088-05S3
The Antiviral Function of the Interferon-Simulated Gene IFIT105/01/2012 - 04/30/2014 (Subcontract PI)
The Washington University NIH NIAID5U01AI083005-04